eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Astellas Pharma Ltd

3rd Floor, Future House, The Glanty, Egham, Surrey, TW20 9AH
Telephone: +44 (0)1784 419615
Fax: +44 (0)1784 419583
Medical Information Direct Line: 0800 783 5018
Medical Information e-mail: medinfo@gb.astellas.com

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 13/04/2011
SPC Lipobase


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Lipobase.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Lipobase contains no active ingredient.


Go to top of the page
3. PHARMACEUTICAL FORM

Cream.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

For use where it is desired by the physician to reduce gradually the topical dosage of Locoid Lipocream. It may also be used where a continuously alternating application of the active product and the base is required e.g. in prophylactic therapy. Application of the Lipobase is also recommended where it is felt by the physician that the use of a bland emollient base is preferable to the cessation of therapy with the active product. Lipobase may also be used as a diluent for the active product in those cases where dilution is regarded as necessary by the prescriber. Lipobase may also be used other than in conjunction with a topical corticosteroid for its emollient action, and for the treatment of mild skin lesions such as pruritus or dry, scaly skin, where topical corticosteroid is not warranted.


Go to top of the page
4.2 Posology and method of administration

For adults, children and the elderly: Lipobase may be used either by replacing an application of the active product or alternating the application of the active product and the base, gradually diminishing the application of the active product until therapy ceases, or by the application of the product for its emollient action.


Go to top of the page
4.3 Contraindications

None stated.


Go to top of the page
4.4 Special warnings and precautions for use

A small number of people may be hypersensitive (allergic) to the constituents of Lipobase.

Cetostearyl alcohol may cause local skin reactions (e.g. contact dermatitis).

Methyl parahydroxybenzoate may cause allergic skin reactions (possibly delayed).


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None stated.


Go to top of the page
4.6 Pregnancy and lactation

None stated.


Go to top of the page
4.7 Effects on ability to drive and use machines

None stated.


Go to top of the page
4.8 Undesirable effects

None stated.


Go to top of the page
4.9 Overdose

None stated.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

The product acts topically as an emollient cream.


Go to top of the page
5.2 Pharmacokinetic properties

Topical administration with no pharmacologically active constituents.


Go to top of the page
5.3 Preclinical safety data

No relevant preclinical safety data has been generated.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Cetostearyl alcohol

Macrogol cetostearyl ether

Light liquid paraffin

White soft paraffin

Methyl parahydroxybenzoate

Sodium citrate, anhydrous

Citric acid, anhydrous

Purified water


Go to top of the page
6.2 Incompatibilities

None stated.


Go to top of the page
6.3 Shelf life

30g, 50g, 100g and 200g packs, 3 years.

200g and 500g packs, 2 years


Go to top of the page
6.4 Special precautions for storage

Do not store above 25°C.


Go to top of the page
6.5 Nature and contents of container

Collapsible aluminium tube with plastic screw cap containing 30 g, 50 g, 100 g or 200 g; and pump dispenser containing 200 g or 500 g.


Go to top of the page
6.6 Special precautions for disposal and other handling

Not applicable.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Astellas Pharma Ltd.

3rd Floor

Future House

The Glanty

Egham

Surrey

TW20 9AH

United Kingdom


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL0166/0125


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

First authorisation granted 19 February 1985

Renewal granted 23 January 2001.


Go to top of the page
10. DATE OF REVISION OF THE TEXT

13th December 2010


Go to top of the page
11. LEGAL CATEGORY

P



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/2259/SPC/


Active Ingredients/Generics

 
   no active ingredients